EZH2 and malignant pleural mesothelioma: While EZH2 inhibitors show promise in malignant pleural mesothelioma treatment, their effectiveness is limited by MSC-mediated oncogene activation, suggesting that targeting monocyte recruitment and depleting TAMs may restore the antitumor activity of EZH2 inhibitors [153].